Actinogen Medical Limited

ACW

AU000000ACW3

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:24 2024-07-12 am EDT			5-day change	1st Jan Change
0.071 ^AUD	-4.05%		+9.23%	+222.73%

Jul. 02	Actinogen Medical Expects Results from XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%	MT
Jun. 26	Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	CI

Actinogen Medical Limited Announces Resignation of Bill Ketelbey as Chief Executive Officer

February 07, 2021 at 10:45 pm EST

Actinogen Medical Limited announced that Dr. Bill Ketelbey, has resigned from his position as Chief Executive Officer of the Company, effective 8 February 2021.

Latest news about Actinogen Medical Limited

Actinogen Medical Expects Results from XanaCIDD Phase 2a Clinical Trial in August; Shares Down 6%	Jul. 02	MT
Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker	Jun. 26	CI
Actinogen Medical's Xanamem Drug 'Potentially Slows' Progression of Alzheimer's Disease	Jun. 26	MT
Actinogen Medical Completes AU$3.9 Million Non-Renounceable Entitlement Offer	May. 29	MT
Actinogen Medical Opens AU$3.9 Million Entitlement Offer; Shares Down 7%	May. 15	MT
Actinogen Medical Lodges Prospectus for Nearly AU$4 Million Entitlement Offer	May. 07	MT
Actinogen Medical Raising Up to AU$8.9 Million for Advancing Trial, Working Capital; Shares Fall 24%	May. 02	MT
Actinogen Medical Limited Announces the Full Enrolment of 167 Participants in the Company's XanaCIDD Phase 2A Clinical Trial in Patients with Cognitive Importive in Major Depressant Disorder	Apr. 22	CI
Actinogen Medical Completes Patient Enrolment for XanaCIDD Phase 2a Trial; Shares Up 3%	Apr. 21	MT
Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial	Apr. 15	CI
Actinogen Doses First Patient in Phase 2b Alzheimer’s Disease Trial; Shares Rally 16%	Apr. 14	MT
Actinogen Medical Notifies of Errors on M&A Slide in Recent Presentation	Mar. 25	MT
Actinogen Medical Initiates Final Enrolment Phase for XanaCIDD Depression Trial; Shares Rise 3%	Mar. 07	MT
Actinogen Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Actinogen Medical Secures UK Innovation Passport for Alzheimer’s Disease Treatment	Feb. 15	MT
Actinogen Medical Activates First Trial Site for Phase 2B Alzheimer’s Disease Trial	Dec. 20	MT
Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial	Nov. 28	CI
Actinogen Medical's XanaCIDD Trial Enrolment Surpasses 50% Milestone	Nov. 28	MT
Actinogen Medical Receives AU$4.8 Million R&D Tax Refund	Nov. 28	MT
Actinogen Medical Names CFO	Nov. 07	MT
Actinogen Medical Limited Announces CFO Changes	Nov. 07	CI
AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston	23-10-13	CI
Actinogen Medical Redesigns Phase 2b Trial of Alzheimer's Disease Drug	23-09-27	MT
Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results	23-09-26	CI
Actinogen Medical Completes AU$10 Rights Issue	23-09-07	MT

Chart Actinogen Medical Limited

Duration

Period

More charts

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The Company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimerâs Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamemâs mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. It has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The Company conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamemâs therapeutic potential.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ACTINOGEN MEDICAL LIMITED	+222.73%	130M
MODERNA, INC.	+22.10%	46.55B
LONZA GROUP AG	+46.45%	41.84B
IQVIA HOLDINGS INC.	-3.12%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+36.10%	32.95B
CELLTRION, INC.	-6.30%	28.27B
ICON PUBLIC LIMITED COMPANY	+18.71%	27.78B
UNITED THERAPEUTICS CORPORATION	+46.15%	14.26B
MEDPACE HOLDINGS, INC.	+44.52%	13.69B
BIO-TECHNE CORPORATION	+0.19%	12.18B

Other Biotechnology & Medical Research